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Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative condition that is characterised
by the loss of specific populations of neurons in the brain. The mechanisms underlying this
selective cell death are unknown but by using laser capture microdissection, the glycopro-
tein, CD24 has been identified as a potential marker of the populations of cells that are
affected in PD. Using in situ hybridization and immunohistochemistry on sections of mouse
brain, we confirmed that CD24 is robustly expressed by many of these subsets of cells. To
determine if CD24 may have a functional role in PD, we modelled the dopamine cell loss of
PD in Cd24 mutant mice using striatal delivery of the neurotoxin 6-OHDA. We found that
Cd24 mutant mice have an anatomically normal dopamine system and that this glycoprotein
does not modulate the lesion effects of 6-OHDA delivered into the striatum. We then under-
took in situ hybridization studies on sections of human brain and found—as in the mouse
brain—that CD24 is expressed by many of the subsets of the cells that are vulnerable in PD,
but not those of the midbrain dopamine system. Finally, we sought to determine if CD24 is
required for the neuroprotective effect of Glial cell-derived neurotrophic factor (GDNF) on
the dopaminergic nigrostriatal pathway. Our results indicate that in the absence of CD24,
there is a reduction in the protective effects of GDNF on the dopaminergic fibres in the stria-
tum, but no difference in the survival of the cell bodies in the midbrain. While we found no
obvious role for CD24 in the normal development and maintenance of the dopaminergic
nigrostriatal system in mice, it may have a role in mediating the neuroprotective aspects of
GDNF in this system.
Introduction
The primary clinical features of Parkinson’s disease (PD)—classically defined as a resting
tremor, bradykinesia, postural instability and rigidity [1]—are associated with a>60% loss of
dopamine (DA) neurons in the substantia nigra pars compacta (SNpc) of the midbrain [2].
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The severe cell loss observed in the SNpc is in contrast, however, with that seen in the adjacent
midbrain DA populations: the ventral tegmental area (VTA) which has only a 40% reduction
in DA cells [2,3] and the retrorubral field (RRF) which exhibits little or no DA cell loss [2,4].
This raises questions as to why the SNpc population of DA neurons is more vulnerable to the
PD disease process.
This selective cell loss is though not restricted to the midbrain DA populations. Post-mor-
tem analysis of brains from early stage PD patients has suggested that the loss of the DA neu-
rons in the SNpc is preceded by cell death in specific nuclei further down the brainstem, in
particular the dorsal motor nucleus of the vagal nerve (DmnV), the raphe nucleus (RN), the
pedunculopontine nuclei (PPN), and the locus coeruleus (LC) [5]. Remarkably, the nuclei
neighbouring these structures remain significantly less affected, again raising questions regard-
ing the selective cell loss associated with PD.
Given all this, one can hypothesize that the susceptible cells may share certain common fea-
tures that makes them vulnerable to the disease, and one such factor that we identified was
CD24 (cluster of differentiation 24; also known as Cd24a, M1/69-J11D heat-stable antigen
(HSA), Lymphocyte antigen 52 (Ly-52), or Nectadrin). CD24 is a glycosyl phosphatidylinositol
(GPI) anchored sialoglycoprotein that is expressed in a variety of tissues [6], and when first
cloned, was associated with T-cell co-stimulation [7]. In lymphoid organs, this feature of Cd24
is redundant, only becoming essential in the absence of Cd28 [8,9]. In “co-stimulator ligand
rich” organs, such as the central nervous system (CNS), however, the role of Cd24 is more criti-
cal. Cd24 deficiency in mouse models of experimental autoimmune encephalomyelitis (EAE)
prevents T-cell proliferation and persistence [10], while conditionally over-expressing the gene
exaggerates the response [11]. It has also been reported that, through an interaction with
SiglecG (in mice) or Siglec10 (in humans), CD24 selectively represses the host response to
injury, discriminating danger-associated molecular patterns (DAMPs) from pathogen-associ-
ated molecular patterns (PAMPs) [12].
Laser capture microdissection gene expression studies have demonstrated that Cd24 is
expressed in the SNpc, but not the VTA [13–15] as well as the DmnV [16] and the LC [17].
Given the shared expression of Cd24 amongst the nuclei specifically affected in PD, and the
direct interaction of Cd24 with the immune system, we sought to determine whether this pro-
tein could have a role in the cell loss seen in PD.
We found that CD24 is expressed in both the mouse and human brain in many of the nuclei
affected pathologically in PD, but curiously not the SNpc in the human brain. Furthermore,
we found using a classical mouse model of PD that while the absence of Cd24 did not impact
on the long-term survival of the DA system, it did affect the neuroprotective effects of Glial
cell-derived neurotrophic factor (GDNF) at the level of the striatal dopaminergic fibres. This
result may be particularly relevant given the absence of CD24 in the SNpc neurons in the
human adult midbrain.
Materials and methods
Mice and post-mortem human tissue
Cd24 knockout mice bred on a C57/Black background were used in this study [18]. The wild-
type (Cd24+/+) and homozygote (Cd24-/-) littermates were housed with unrestricted access to
food and water. All animal procedures were performed in accordance with Cambridge Univer-
sity animal care committee regulations. Experiments were performed under the Home Office
licences PPL 80/2366 (expired April 2016) or 70/8411 (valid until 2020).
Samples of human tissue were obtained from the Parkinson’s UK Tissue Bank, funded by
Parkinson’s UK, a charity registered in England and Wales (258197) and in Scotland
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nucleus; VTA, Ventral tegmental area; V, Motor
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(SC037554), and from the Cambridge Brain Bank at Addenbrooke’s Hospital (Cambridge)
which is supported by the NIHR Cambridge Biomedical Research Centre. Handling of human
tissue was done according to the UK Human Tissue Act 2006. Ethical approval for the research
conducted in this current study was granted by the Cambridge Central Ethics (ref no 01/177).
Behavioural testing
Cylinder test. The cylinder test was conducted as previously described with rats [19,20].
Briefly, the mice were placed in a glass cylinder (13cm wide; 18 cm high) with two vertical mir-
rors positioned behind it, allowing for the paws of each mouse to be visualised at all times.
Recordings were made with a Logitech c170 webcam, commencing as soon as the mouse was
placed in the cylinder, and were analysed by an experimentally blind investigator (before geno-
typing). Six recordings lasting 3 minutes each were made over the last nine days before the
mice were sacrificed. The first 20 wall contacts were counted in each session, and the frequency
of ipsilateral (same side as the lesion) versus contralateral paw contacts was determined. Full
extension of the digits of each paw was required for the contact to be counted.
Amphetamine induced rotations. Amphetamine induced rotations were induced on
the day before the mice were to be sacrificed. The mice were injected intraperitoneally with
2.5mg/kg of amphetamine and placed in glass cylinders (13cm wide; 18 cm high). The number
of rotations over 50 minutes was recorded on a Logitech c170 webcam and counted by an
experimentally blind investigator. The number of full rotations was recorded for 1 minute
every 5 minutes, and expressed as the net number of ipsilateral turns/min.
Open field locomotion test. The open field locomotion measure was conducted on the
day before sacrifice. It involved a 10-minute recording session in which the mice were placed
in an arena (70cm x 55cm x 22cm), with a Logitech c170 webcam recording the movement of
the mice from above the enclosure. Footage of the test session was analysed using Icy "Mice
Profiler Tracking" software (http://icy.bioimageanalysis.org/) [21,22].
Stereotaxic injections
The mice were anesthetized with isoflurane, placed in a stereotaxic frame, and were unilater-
ally lesioned in the striatum (co-ordinates: AP: +1.5; ML: +0.21; DV: 3.0). A small hole was
drilled in the exposed skull and a Hamilton syringe was used for the delivery of the 6-OHDA
(5μg/μl; 1.5μl in total, at a rate of 0.5μl per minute). The syringe was left in place for 5 minutes
before being slowly removed. The mice were then sutured and allowed to recover until either
12 or 70 days post-surgery. Special husbandry was provided post-surgical procedures, with
mice being weighed daily and provided with subcutaneous injections of warm saline (at least
0.3ml/day), mashed pellets, and chocolate balls (Supreme Mini Treats from Datesand) to pre-
vent weight loss.
Tissue processing
Mouse. The mice used in this study were euthanized with a 0.3 ml intraperitoneal injec-
tion of Euthatal (pentobarbitone sodium, 200 mg/ml; Merial, UK). They were then perfused
transcardially with either 0.9% saline followed by ice-cold 4% paraformaldehyde (0.1 M phos-
phate buffer, pH 7.4) or formalin solution (10%; Sigma Aldrich). Brains were removed and
post-fixed in their respective solutions overnight. The PFA fixed brains were then shifted to
30% sucrose, while the formalin fixed brains were washed in PBS and switched to 70% ethanol
for paraffin embedding.
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Human. Post-mortem tissues obtained from both the Parkinson’s UK brain bank at
Imperial College (London) and the Addenbrooke’s Brain Bank, were sectioned at source and
provided as either fresh frozen sections (12μm thick) or paraffin embedded sections (6μm).
Immunohistochemistry
Perfused brains were sectioned coronally at 35 μm intervals using a sledge microtome (Leica
SM 1400) and collected in 6 series in antifreeze-based solution. Immunohistochemistry was
performed as previously described [23]. Briefly, free-floating sections were washed in 0.1M
phosphate buffer saline (PBS) before being quenched for 20–30 min in 3% H2O2 and 50%
methanol. The sections were then washed in PBS again, before being incubated overnight in
5% normal horse serum plus 0.05% Triton X-100 in PBS at room temperature with a primary
antibody recognizing Rat-CD24 (M1/69; sc-19651, 1:50; Santa Cruz), rat-dopamine trans-
porter (DAT; 1:200; MAB369, Chemicon), Goat-GDNF (1:500; AF-212-NA; R&D systems),
and Rabbit-TH (1:1000, Pelfreez). A one-hour incubation with an appropriate biotinylated sec-
ondary antibody (1:200; Vector Laboratories, Burlingame, CA) was followed by an additional
40-minute incubation in avidin-biotin-peroxidase solution (ABC Elite; Vector Laboratories).
Finally, visualization of the bound antibody was done using 3’-diaminobenzidine (DAB;
Sigma). The sections were then mounted on gelatin-coated glass slides, dehydrated in escalat-
ing ethanol concentrations, cleared in xylene, and cover slipped with DEPEX Mounting
Medium.
Immunofluorescence was performed using the antibodies mentioned above, in addition to
other commercially available antibodies: Rabbit-ALDH1A1 (1:200; ab24343, Abcam), Rat-
CD11b (1:500; RnD systems), Rat-CD24 (1:50; Santa Cruz), Rabbit-GFAP (1:500; DAKO),
Mouse-GFAP (1:500; Abcam), rabbit anti-Girk2 (1:100, APC-006, Alomone Labs), Rabbit-TH
(1:1000, Pelfreez), Mouse-TH (1:500, Millipore), and Sheep-TH (1:1000, Millipore). Sections
were incubated overnight with combinations of primary antibodies in 5% normal donkey
serum plus 0.05% Triton X-100 in PBS at room temperature. Expression was visualised the
next day with fluorescent secondary antibodies (Alexafluror 488, 568, & 688; 1:500, Invitro-
gen). The sections were mounted on gelatin-coated slides and cover slipped with Flurosave
(Millipore).
In situ hybridization
In situ hybridization analysis was conducted on sections of mouse and human brain using
the RNAscope Target Probes (Advanced Cell Diagnostics) according to the manufacturer’s
instructions. For mouse Cd24, the probes targeted the 273–1419 base pair region of the gene
(Accession No. NM_009846.2), and for human CD24, the probes targeted the 458–2142 base
pair region of the gene (Accession No: NM_013230.2).
Stereological estimations
To quantify the number of TH+ cells in the substantia nigra randomised counts were per-
formed using a standard stereological method (Olympus CAST Grid System) [24]. This analy-
sis was conducted as previously described [23]. Briefly, the substantia nigra was defined by a
ventral border passing from the lateral extremity of TH+ cells, down along the dorsal border
of the cerebral peduncle to the medial tip of this structure. A vertical line was passed through
the medial tip of the cerebral peduncle and represented the medial border of the substantia
nigra. The dorsal border of the area of interest extended dorso-laterally along the upper limits
of the TH+ cell bodies in the SNpc. On sections where the medial lemniscus was present, TH
+ cells superior to this structure were not counted—thus excluding the TH+ cells of the VTA.
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For all brains, five sections of substantia nigra (at approximately 200μm intervals, between
−2.5 and −3.8 relative to Bregma) were counted using a 20x lens. The intact/unlesioned side of
the brain was counted with a grid size that was 180x180μm, with the counting frame measur-
ing 80x80μm, while the lesioned side of the brain required a grid size that was 150x150μm,
with the counting frame measuring 100x100μm. At least 200 cells were counted per side of the
brain and estimates of the total number of neurons were calculated according to the optical
fractionator formula, and only a coefficient of error of<0.10 was accepted [25].
Optical density analysis
All of the DAB stained slides in this study were imaged using the scanscope XT slide scanner
(Aperio), at a resolution of 0.5 microns per pixel, using a x20 objective. To quantify the fibre
density in the striatum and Substantia nigra pars reticulata (SNpr), the mean optical intensity
was measured from the TH-positive stained sections [26,27]. For the striatum, the measure-
ments were conducted on 12 coronal levels at intervals of approximately 210μm, correspond-
ing to sections of the structure from between +1.7 and -1.4 relative to bregma. The area of
interest did not include the nucleus accumbens and globus pallidus. Fibre density analysis on
TH+ fibres of the SNpr was conducted on only 2 coronal sections per brain (210 μm apart;
from approximately -2.7 to -3.2 according to Bregma) in the rostral SNpc as only TH+ fibres
(and no TH+ cell bodies) are present there. Nonspecific background was determined by taking
measurements from the TH-negative corpus callosum and normalizing it to the white light
background surrounding the section on the glass slide. This analysis was conducted using Ima-
geJ (version 1.42q for Mac OSX, from the National Institutes of Health; http://rsb.info.nih.
gov/ij/).
Statistical analysis
All statistical analyses were performed using Prism (version 5.0; Graphpad Software, San
Diego, CA, USA). The number of animals and statistical tests used in each experiment is pro-
vided in the Results section and in each figure legend (Mann-Whitney (M-W) or ANOVA).
For optical density experiments, comparisons were made between the lesioned and intact side
of the brain to avoid between-section differences in antibody staining. For all of the stereologi-
cal estimations of TH+ cells in the midbrain, the lesioned side of the brain was compared with
the intact side. Differences were considered significant when P < 0.05 (P< 0.05; P< 0.005;
P< 0.0005). Percentages are presented with the standard error (SE) in both the text and
figures.
Results
The expression of Cd24 transcripts in the adult mouse brain
Using in situ hybridization, we examined Cd24 transcript expression in the adult mouse brain,
confirming and extending those that have been previously reported (Allen Institute for Brain
Science. Allen Mouse Brain Atlas [Internet]. Available from: http://mouse.brain-map.org/
experiment/show/79591541). Here we shall focus exclusively on those nuclei that are majorly
affected in PD, but a full description of Cd24 expression in the adult mouse brain can be found
in S1 Fig. When considering the nuclei preferentially affected in PD [28], we find that Cd24
expression in the adult mouse brain overlaps with many of these structures. In the forebrain,
robust Cd24 transcript expression is present in the olfactory bulbs (S1A and S1B Fig), though not
the anterior olfactory nucleus [29]. We also found strong expression in the amygdala (Fig 1A)
CD24 and the midbrain dopamine neurons
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Fig 1. In situ hybridization of Cd24 expression on the adult mouse brain. (A) A coronal image of Cd24 expression (in red) in the central
amygdala nucleus (Amg). (B) Cd24 transcripts labelling the Substantia nigra pars compacta (SNpc; arrows) in the midbrain. The dashed line
boxed area in B corresponds to the panel in C. (C) Cd24 expression in the SNpc, overlaid with tyrosine hydroxylase (TH) immunofluorescent
staining. (D) A more caudal section of the SNpc to panel C, demonstrating the lack of Cd24 expression in the ventral tegmental area (VTA).
(E) High magnification image of the dashed line boxed area indicated in panel D illustrating the dopamine neuron-specific expression of
Cd24 in the SNpc. (F) A similar image to that of panel E (of the dashed line boxed area indicated in panel D), demonstrating the lack of Cd24
expression in the dopamine neurons of the VTA. (G) In the hindbrain, Cd24 transcripts overlapped with the TH+ neurons of the locus
coeruleus (LC) and also labelled the parabrachial nucleus (PBl) and the motor nucleus of trigeminal nerve (v). (H) Further down the
brainstem, in the medulla, Cd24 expression was present in the dorsal motor nucleus of the vagal nerve (DmnV), the area postrema (AP),
and the hypoglossal nucleus (XII). The scale bar in panel H represents 200μm in panel A&H, 500μm in panel B, 100μm in panels C, D and
G, and 50μm in panels E and F.
doi:10.1371/journal.pone.0171748.g001
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[30], but not in the nucleus basalis of Meynert although it was present at high levels in the reticu-
lar nucleus of the thalamus (S1I Fig).
In the mesencephalon, Cd24 transcripts are present in the DA neurons of the SNpc (Fig
1B), as confirmed using double immunofluorescent staining for tyrosine hydroxylase (TH—
the rate limiting enzyme involved in DA production; Fig 1C). Quantifications of TH+ cell bod-
ies with more than two red separate aggregations of signal amplification inside the cytoplasm
indicated that 60.8%±3.1 of the cell bodies in the SNpc are TH+/Cd24+, 31.2%±3.7 are TH
+/Cd24- and 8.0%±1.2 are TH-/Cd24+ (n = 3 brains). Double staining with astrocyte (GFAP)
and microglial (CD11b) markers found no/little co-localisation in the SNpc and VTA regions
(data not shown). Cd24 expression in the SNpc is more robust in the rostral portion than more
caudal aspects (compare Fig 1D and 1C), and in agreement with others we found very little
expression of Cd24 in the VTA when compared to the SNpc [14] (Fig 1E and 1F). This suggests
that Cd24 is a gene that is preferentially expressed by the SNpc DA neurons, which are classi-
cally recognised as one of the most affected subsets of cells in the PD brain [2,28].
In the hindbrain, we detected strong labelling of Cd24 in the LC and parabrachial nucleus
(PBl; Fig 1G) [31], and sparse expression in the dorsal raphe nuclei (RN) and Pedunculopon-
tine nuclei (PPN; S1K Fig) [32] as well as the DmnV (Fig 1H). While numerous nuclei in the
adult mouse brain express Cd24, we considered it noteworthy that many of them (such as the
amygdala, SNpc, RN, PPN, PBl, LC, and DmnV) are sites of major pathology in PD [28], while
others low in expression (e.g. VTA) are relatively well preserved in this condition.
CD24 protein expression in the mouse brain
We followed up the in situ analysis by looking at the protein expression of CD24 in the adult
mouse brain. Again, we have focused on the nuclei affected in PD, although a comprehensive
representation of CD24 protein localisation is provided in S2 Fig. As previously reported [33],
robust CD24 expression was observed in the olfactory bulb (especially the glomerular layer
and rostral migratory stream; S2A Fig). We also found a dorsal-ventral gradient of CD24
expression in the rostral striatum (Fig 2A), and strong CD24 expression in the amygdala (S2D
Fig). In the midbrain, we observed weak CD24 staining labelling in the SNpc (Fig 2B; S2E–
S2G Fig) with double immunofluorescent staining showing low expression of CD24 on the
surface of the DA cell bodies—particularly the neurites and dendritic fibres, but no staining in
the cytoplasm (Fig 2C and 2D), indicative of a membrane bound protein.
In the hindbrain, we observed very little/no CD24 protein in the raphe nucleus (S2H Fig),
and moderate CD24 expression in the cell bodies of the LC (Fig 2E). In the medulla, we found
CD24 protein in the DmnV (data not shown). Importantly, while again highlighting an expres-
sion profile that strongly overlaps with the sites of PD pathology, the presence of CD24 on the
neurites of the DA neurons in the SNpc led us to investigate further the possible function of
CD24 in these cells.
The dopamine system of the Cd24 mutant mouse is anatomically normal
To determine whether Cd24 has a role in the development or maintenance of the midbrain
DA neurons, we analysed the brains of mice that had a targeted deletion of the gene [18].
Immunohistochemistry for CD24 on sections of brain tissue derived from 8week old Cd24-/-
mice exhibited no labelling, demonstrating that CD24 protein was not present in the brains of
these mice (S2I–S2L Fig). Further, TH staining on those same sections indicated no observable
difference in the DA system between Cd24-/- mice and Cd24+/+ littermates. In the olfactory
bulb, the dopaminergic interneurons in the glomerular layer were in the correct location. The
TH+ fibre innervation of the striatum appeared unaltered by the mutation, and stereological
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Fig 2. CD24 protein expression pattern in the adult mouse brain. (A) CD24 expression in the mouse forebrain at two
levels of the striatum. (B) Coronal sections of the midbrain at the level of the caudal end of the mammillary bodies (MM). TH
staining on the left section indicates the location of the dopamine neurons of the SNpc. CD24 labels DA neurons in the SNpc,
as well as the lateral posterior thalamic nucleus (LPMC), superior colliculus (SC), and nuclei surrounding the medial
geniculate (MG). (C) Immunofluorescent staining of TH and CD24 indicates some localisation in the SNpc. Dashed line
box highlighting area of the high magnification image in panel D. (D) CD24 staining on TH+ DA neurons in the SNpc, labelling
dendritic fibres projecting down into the substantia nigra pars reticulata (SNpr). (E) TH and CD24 staining in the hindbrain
CD24 and the midbrain dopamine neurons
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estimations of TH+ cells in the SNpc indicated that the absence of Cd24 did not affect the
number of DA neurons in this subregion (Fig 3A; 9422.53±548.3 TH+ cells in the Cd24-/-
SNpc compared with 9353.2±489.3 in the Cd24+/+mice; M-W U = 5, p = 0.86; n = 5 animals
per group).
To determine whether the absence of Cd24 resulted in increased vulnerability for DA neu-
rons with aging, we assessed the Cd24-/- mice at 2 years of age. These aged mice displayed no
difference in the distance travelled in an open field measure of locomotion (Fig 3B; 25.93±2.69
meters of distance covered by Cd24-/- mice compared to 23.46±4.27 for the Cd24+/+ group;
M-W U = 10, p = 0.98; n = 4 animals per group) nor in the number of TH+ neurons in the
SNpc (Fig 3C; 8962.71±89.8 TH+ cells in the Cd24+/+SNpc compared with 9087.19±566.2 in
the Cd24-/- mice; M-W U = 4, p = 0.9; n = 4 animals per group). There was no obvious ana-
tomical differences in the dopamine system of the 2 year old Cd24-/- mice (S3 Fig), including
the fibre innervation of the striatum (Fig 3D and 3D’) and the morphology of the TH+ cells in
the SNpc of Cd24-/- mice (Fig 3E–3F’), when compared to their Cd24+/+ littermates. These
mutant mice also displayed the correct expression patterns for SNpc-related genes such as G
protein-activated inward rectifier potassium channel 2 (Girk2), and aldehyde dehydrogenase 1
family, member A1 (Aldh1a1; data not shown) [34–36]. Together these findings suggested that
Cd24 does not play a critical role in the normal anatomical development and maintenance of
the murine midbrain DA system. Whether it has a more subtle role in the synaptic release of
DA within the striatum was not explored in this study, but may be worth investigating given
the putative role of this molecule at the neuromuscular junction [37].
CD24 has no effect on striatal 6-OHDA lesions in mouse models of PD
Several reports have highlighted the importance of T-cells in the neurodegeneration associated
with neurotoxic and other relevant animal models of PD [38,39]. Given that Cd24 deficient
mice exhibit reduced T-cell proliferation and persistence in models of EAE [10] and condi-
tionally over-expressing the gene exaggerates the phenotype [11], we hypothesized that dele-
tion of the gene may lessen the effect of the neurotoxin 6-OHDA on the long term survival of
midbrain DA neurons. Blocking CD24 with antibodies in mice has been shown to not be pos-
sible due to toxicity issues ([40] and Prof Peter Altevogt, personal communication), and so we
modelled PD in the Cd24-/- mouse using striatal delivery of 6-OHDA.
The delivery of the neurotoxin 6-OHDA to the midbrain nigrostriatal pathway is com-
monly used to model the DA pathology of PD. Injecting 6-OHDA into the medial forebrain
bundle or the SNpc results in a very rapid loss of TH+ cells [41,42], which does not allow for a
thorough analysis of the molecular events involved in the loss of cells within the midbrain. To
circumvent this, we have previously demonstrated that 6-OHDA delivery to the striatum
results in a slower rate of midbrain TH+ cell loss, beginning between 9–12 days post lesion,
coinciding with local glial activation [23]. Thus, we chose to adopt this approach given also the
possible role of Cd24 in modulating neuroinflammatory processes to injury. This also explains
why we examined the brains of the Cd24-/- and Cd24+/+ mice over this period of cell loss fol-
lowing surgery.
At 12 days post-lesion, we found no difference between genotypes in the fibre density of
TH+ axonal arborisations in the striatum (33.4%±6.9 of the unlesioned side in the Cd24-/-
mice compared with 33.3%±7.2 for the Cd24+/+mice (n = 5 in both groups); M-W U = 10,
where the LC is labelled by both. Co-ordinates in the right hand corners of panels A, B & E indicate the location of the coronal
plane relative to bregma. The scale bar in panel A represents 800μm in panel A&E, 500μm in panel B, 200μm in panel C, and
50μm in panel D.
doi:10.1371/journal.pone.0171748.g002
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Fig 3. The midbrain dopamine system of the Cd24 mutant mouse is normal. (A) Stereological estimations of the
number of SNpc TH+ cells at 8 weeks of age. (B) Distance travelled in the open field arena by 2-year-old Cd24-/- and
Cd24+/+ mice. (C) Stereological estimations of the number of SNpc TH+ cells at 2 years of age. (D) Tyrosine hydroxylase
(TH) immunohistochemistry on coronal sections of a brain of a 2-year-old Cd24-/- mouse (left column) and a Cd24+/+
littermate (right column), at the level of the striatum. (E) A coronal section of the SNpc at the level of the fasciculus
retroflexus (FR) and the caudal end of the mammillary bodies (MM). (F) Images of the VTA and SNpc at the level of the
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p = 0.998; Fig 4A and 4C) or the TH+ dendritic branchings in the SNpr (76.9%±6.3 of the
unlesioned side compared with 68.0%±2.5 for the Cd24+/+ mice; M-W U = 6, p = 0.38; Fig 4B
and 4D). We also observed no difference in the number of SNpc TH+ neurons using stereo-
logical estimations at 12 days post-surgery (86.6%±4.2 of the unlesioned side for Cd24-/- mice
compared to 88.3%±2.2 of the unlesioned side for Cd24+/+ mice; M-W U = 5, p = 0.74; Fig
4E).
To determine whether the absence of CD24 had any long-term consequences on the sur-
vival of the DA neurons, we next examined the 6-OHDA-striatal lesioned mice 70 days post-
lesion—a time point when the pathological changes linked to the lesion are known to be com-
plete [43]. Before culling the mice, we performed behavioural testing which included the cylin-
der test, amphetamine induced rotations, and open field locomotion. We found no difference
between the mice in any of these tests (Cylinder test: affected forelimb usage was 64.3±8.7% of
unaffected forelimb in the Cd24-/-mice vs 59.3±7.7% in the Cd24+/+ at 70 days post-6-OHDA
lesion, M-W U = 27.5, p = 0.66; compared with 103.8±5.7% in non-lesioned Cd24+/+ control
mice; Amphetamine induced Rotations: 4.17±1.01 rotations per minute in the lesioned Cd24-/-
mice vs 3.45±1.3 in the lesioned Cd24+/+ mice, M-W U = 11.5, p = 0.33; Open field test: 22.15
±2.28 meters of distance covered in the lesioned Cd24-/- mice vs 25.96±2.8 meters in the
lesioned Cd24+/+, M-W U = 9, p = 0.18; compared with 27.14±1.51 meters in non-lesioned
Cd24+/+ control mice, Fig 5A; n = 8 in each group). Histologically there was no difference in
TH+ fibre density in the striatum (27.2±4.1% of unlesioned striatum compared to 31.1±5.8%
in the Cd24+/+ mice; M-W U = 20.5, p = 0.41; Fig 5B, 5E and 5E’; n = 8 in each group) nor in
the SNpr (44.3±2.7% of unlesioned SNpr, compared to 39.9±5.5% in the Cd24+/+ mice; M-W
U = 25, p = 0.75; Fig 5C and 5F–5G’). Stereological estimations of the number of TH+ cells in
the SNpc showed no significant differences between Cd24-/- and Cd24+/+mice (20.8±2.5% of
unlesioned SNpc, compared to 25.9±3.8% in the Cd24+/+ mice; M-W U = 15, p = 0.15; Fig 5D
and 5F–5G’). Collectively, these results suggest that Cd24 has no impact on the long-term sur-
vival of the SNpc DA neurons following a 6-OHDA striatal lesion.
CD24 is involved in the neuroprotective effect of GDNF
Given that the absence of Cd24 had no impact on the overall survival of SNpc DA neurons in
the 6-OHDA model of PD, we next sought to determine whether Cd24 may have more of a
role in mediating the neuroprotective effects of GDNF. Christophersen et al [44] reported a
nine fold increase in Cd24 expression in the substantia nigra following lentiviral delivery of
GDNF into the striatum. Thus, we reasoned that Cd24 may be involved in some aspect of the
neuroprotective effects of GDNF. To test this hypothesis, we delivered AAV-GDNF into the
striatum of both WT and Cd24-/-mice.
One-month post-surgery, robust GDNF expression was observed in the striatum of both
groups of mice (optical density analysis indicated a 440.4±56.9% increase in GDNF staining in
the injected striatum compared to the uninjected side of the Cd24-/- mice versus with 428.7
±75.7% in the injected Cd24+/+ mice; M-W U = 12, p = 0.94; S4A Fig). Both sets of mice also
exhibited a reduction in body weight in accordance with previous reports [45], suggesting that
GDNF functions normally in Cd24-/- mice. Increased levels of CD24 were present in the SNpc
of the transfected side of the brain in the Cd24+/+ mice, but absent (as one would expect) in
the Cd24-/- mice (S4B and S4B’ Fig).
medial terminal nucleus of the accessory optic tract (mtn). Co-ordinates in the right-hand corners of panels D, E and F
indicate location of the coronal plane relative to bregma. The scale bar in panel F represents 1cm in panel D, 200μm in
panel E, and 300μm in panel F.
doi:10.1371/journal.pone.0171748.g003
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Two months post-AAV-GDNF transfection, both groups of AAV-GDNF injected mice
(and a control group of WT mice; n = 5 in each group) received a striatal delivery of 6-OHDA
on the same side of the brain. By 21 days post lesion, the loss of TH+ fibres in the striatum has
plateaued and remains stable. When we compared the 21 day time point data with that of 70
days post lesion (see above), we found TH+ fibre loss of 39.8%±7.2 of intact side and 38.2%
Fig 4. The absence of Cd24 has no effect on dopaminergic neuronal survival or fibre innervations in the striatal
6-OHDA lesioned mouse model of Parkinson’s disease. (A) Tyrosine hydroxylase (TH) immunohistochemistry on
coronal sections of brain from a 6-OHDA lesioned Cd24-/- mouse (left column) and a Cd24+/+ littermate (right column) at
12 days post-surgery, at the level of the striatum. (B) Representation sections of midbrain (from the respective brains
provided in panel A) illustrating the loss of TH+ cells on the 6-OHDA lesioned side of the brain. (C) Optical density analysis
of the TH+ fibres in the striatum indicated no difference between the genotypes. (D) Optical density analysis of the TH
+ fibres in the SNpr also showed no significant difference between the genotypes. (E) Stereological estimations of the
number of SNpc TH+ cells found no difference between the Cd24-/- and Cd24+/+ mice. Co-ordinates in the right-hand
corners of panels A indicate location of the coronal plane relative to bregma. The scale bar in panel A represents 1cm and
500μm in panels B.
doi:10.1371/journal.pone.0171748.g004
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Fig 5. No difference in the long-term structural and functional integrity of the nigrostriatal pathway in the absence of Cd24 in the
6-OHDA mouse model of Parkinson’s disease. (A) Distance travelled in the open field arena by 6-OHDA lesioned Cd24-/- and Cd24+/+
mice at 70 days post-surgery, compared to an unlesioned group of Cd24+/+ mice. (B) Optical density analysis of the TH+ fibres in the
striatum indicated no difference between the genotypes. (C) Optical density analysis of the TH+ fibres in the SNpr also showed no difference
between the genotypes. (D) Stereological estimations of the number of SNpc TH+ cells found no difference between the Cd24-/- and Cd24
+/+ mice. (E) Coronal sections at the level of the striatum illustrating the unilateral loss of TH+ fibres in the Cd24-/- (left) and Cd24
+/+littermate (right). (F) Coronal sections of the midbrain at the level of the fasciculus retroflexus (FR) demonstrating TH+ cell loss in the
rostral SNpc of the Cd24-/- (left) and Cd24+/+ littermate (right). (G) Sections of midbrain at the level of medial lemniscus (ML) intersecting
the VTA and SNpc illustrating TH+ cell loss. Co-ordinates in the corners of panels E, F and G indicate location of the coronal plane relative to
bregma. The scale bar in panel E represents 1cm in panel E, and 600μm in panels F and G.
doi:10.1371/journal.pone.0171748.g005
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±8.6 for the 21 and 70 day timepoints, respctively (M-W U = 12, p = 0.43; S5A and S5B Fig). A
similar stability is also observed in the number of TH+ cell bodies SN (36.6%±2.9 of intact side
for 21 days compared to 35.5%±10.1 for 70 days; M-W U = 11, p = 0.34; S5C and S5D Fig),
indicating that the 21 days time point can be used to determine the final extent of the lesion in
this striatal 6-OHDA model.
At three weeks post-6-OHDA lesion, we found no difference in the reduction of SNpc DA
neurons on the lesioned side of the brain when comparing the two groups of AAV-GDNF
injected mice (93.5±5.0% of the unlesioned side in the Cd24-/- mice compared with 96.2
±3.2% in the Cd24+/+ mice; M-W U = 10, p = 0.66; Fig 6A–6E). In the group of WT mice that
received striatal delivery of 6-OHDA, but no AAV-GDNF, only 36.6±2.9% of the SNpc TH
+ neurons remained compared to the intact side (Fig 6E). These results suggest that CD24 is
not involved in the neuroprotective effects of GDNF at the cell body level. However, when we
conducted optical density analysis of the TH+ fibres in the striatum, we did observe a signifi-
cant difference between the two groups of mice that received AAV-GDNF (53.5±6.8% of the
intact side in the Cd24-/- mice compared with 86.8 ±5.1% in the Cd24+/+ mice; M-W U = 0,
p = 0.0079; Fig 6F–6M; S4C–S4F0 Fig). The same result was also observed with Dopamine
Transporter (DAT) staining (Fig 6K and 6L), indicating that the effect was not specific for TH.
This result indicates that CD24 plays a role in the GDNF-induced neuroprotection of DA neu-
rons at the level of the striatal neurites, which also fits with our earlier expression data on
CD24.
CD24 expression in the human brain
Finally, in order to compare these mouse results with the human situation, we looked at CD24
expression in the human brain. Attempts to label CD24 transcripts on post-mortem brain tis-
sue using conventional in situ hybridization procedures proved very difficult. DIG-labelled in
situ probes provided little if any signal above background (including the use of previously pub-
lished protocols [46]; on both paraffin embedded and fresh frozen tissue from 5 brains; average
post-mortem interval = 22hrs; range = 6–47 hours). To resolve this situation, we utilised a
DNA-branching protocol (RNAscope, Advanced Cell Diagnostics). Using this approach on
fresh frozen, PFA-fixed sections (from 5 normal brains and 5 PD brains supplied by the Par-
kinson’s UK Brain Bank; Table 1), we successfully investigated CD24 expression across 9
regions of the brain: medulla, pons, midbrain, amygdala, thalamus, subventricular zone (SVZ),
hippocampus and frontal cortex.
Control and Parkinson’s disease (PD) brains used in the present study, with their age of
death, sex, post-mortem interval (PMI), and pathological features (based on the pathologist’s
notes). For the PD brains, the duration of disease is also provided. The brains supplied by the
Parkinson’s UK Brain bank are indicated in the grey boxes.
Overall, we found less wide spread expression of CD24 when compared to the mouse brain.
There was also little difference in transcript expression between normal and PD brains, except
in cases where reduced cell numbers in particular nuclei resulted in less labelling. In the brain
stem, we observed strong CD24 expression in the large cell bodies of the DmnV (Fig 7A and
7B) and the hypoglossal nucleus of the medulla, with the transcripts being found in the
nucleus, cytoplasm and extending into the neurites. CD24 was also expressed by large cell bod-
ies in the nucleus ambiguous (Fig 7A and 7C) but we were unable to localise the LC on any of
the samples of the pons. In the midbrain, the lining of the ventricles robustly expresses CD24,
but the neuromelanin+ cells of the VTA and SNpc exhibited no CD24 expression. A very small
fraction of the medially-located neuromelanin+ cells per section were very weakly positive for
CD24 (Fig 7D and 7E), but the more laterally positioned SNpc neuromelanin+ cells were
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Fig 6. CD24 is important for the neuroprotective effect of GDNF on dopaminergic fibres, but not cell bodies, in the 6-OHDA striatal
lesion model of PD. (A-D) Tyrosine hydroxylase (TH) immunohistochemistry on coronal sections of a midbrain from AAV-GDNF
transfected—6-OHDA lesioned Cd24-/- mouse (left column) and a Cd24+/+ littermate (right column) at 12 days post-surgery, at the level of
the rostral SNpc. (A&B) and caudal SNpc (C&D). (E) Stereological estimations of the number of SNpc TH+ cells found no difference with
AAV-GDNF treatment in the 6-OHDA lesioned Cd24-/- and Cd24+/+ mice, but there is a severe reduction in the 6-OHDA only lesioned Cd24
+/+ mice (controls). (F) Optical density analysis of the TH+ fibres in the striatum indicated a significant difference between the AAV-GDNF/
6-OHDA lesioned Cd24-/- and AAV-GDNF/6-OHDA Cd24+/+ mice. (G-L) TH staining of fibre loss in the rostral (G and H), medial (I and J)
and caudal (K and L) striatum from an AAV-GDNF/6-OHDA lesioned Cd24-/- mouse (left column) and a AAV-GDNF/6-OHDA Cd24+/+
littermate (right column). Panels K&L were stained with DAT, indicating that the effect was not specific for TH. (M) A dot-plot graph
comparing the reduction in TH+ cells in the SNpc with the loss of TH+ fibres in the striatum. Black boxes represent Cd24+/+ that received
both AAV-GDNF and 6-OHDA, white boxes represent Cd24-/- that received both AAV-GDNF & 6-OHDA, and grey boxes represent Cd24
+/+ (controls) that received only 6-OHDA. The arrows in panel M indicate the two mice that are presented in panels A-D & G-L. The scale bar
in panel D represents 400μm in panels A-D, and 800μm in panels G-L.
doi:10.1371/journal.pone.0171748.g006
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completely void of CD24 transcripts (Fig 7D and 7F). We supplemented the number of mid-
brain sections with tissue collected from the Cambridge Brain Bank (6 controls and 2 PD;
Table 1), but we found only one of the 11 control brains and none of the 7 PD brains exhibited
CD24 expression in the SNpc neuromelanin+ cells (control brain CT03 on Table 1). Although
this brain exhibited no disease-related pathology in the midbrain, there was unexplained scle-
rosis in the hippocampus, indicating the possibility of some additional complication in this
case that may have affected the staining.
Similar to the mouse brain, we found very strong CD24 transcript signal present in all
areas of the SVZ examined (Fig 7G). In the hippocampus, we found robust CD24 transcripts
in the dentate gyrus, CA2 and CA3 regions, but not CA1 or CA4 (Fig 7H). The amygdala
exhibited weak CD24 expression (Fig 7I), with transcripts also found in layer 3 of the neigh-
bouring periamygdaloid cortex. In the cortex, we found weak CD24 expression in layers 1–3,
and little or no expression in the lower levels (data not shown). Collectively, these results
indicate that CD24 expression in the human resembles the mouse in many areas of the brain,
but importantly it appears to be absent in the neuromelanin+ dopamine neurons of the
midbrain.
Discussion
Understanding the mechanisms involved in the selective cell death associated with PD
would represent a major step forward in better understanding and possibly treating this
condition. We hypothesized that the nuclei preferentially affected in PD may share a com-
mon feature that renders them vulnerable to the causative agent/conditions. Given the spe-
cific expression and interactions of CD24 in mice, we considered this gene to be worthy of
further investigation.
Table 1. List of post-mortem brains used in the current study.
CONTROL BRAINS
BRAIN AGE SEX PMI DURATION PATHOLOGICAL FEATURES
CT01 76 F 6 N/A Normal/unremarkable brain
CT02 67 M 14 N/A Normal/unremarkable brain
CT03 56 M 22 N/A Normal (Unexplained hippocampal sclerosis)
CT04 61 F 71 N/A Normal. Mild loss neurones in the SNpc, but no lewy bodies or pale bodies. Unremarkable brain.
CT05 78 M 77 N/A Alzheimer’s Braak 3—insufficient for a diagnosis
CT06 82 F 26 N/A Normal/unremarkable brain
CT07 84 M 48 N/A Brain oedema; small thalamic infarct
CT08 71 M 52 N/A Mild hypoxic changes
CT09 77 M 48 N/A Presence of Marinesco bodies in SNpc
CT10 81 F 15 N/A Some microvascular chages
CT11 74 F 29 N/A Normal/unremarkable brain
PARKINSON’S DISEASE BRAINS
BRAIN AGE SEX PMI DURATION PATHOLOGICAL FEATURES
PD01 77 M 46 N/A Parkinson’s disease—Braak 2
PD02 89 F 34 N/A Parkinson’s disease—Braak 3
PD03 70 F 42 23 Parkinson’s disease—Braak 3
PD04 88 F 53 7 Parkinson’s disease—Braak 4
PD05 78 M 16 10 Parkinson’s disease—Braak 4 + AB path
PD06 80 M 46 14 Parkinson’s disease—Braak 4 + AB path
PD07 84 M 42 10 Parkinson’s disease—Braak 4 + AB path
doi:10.1371/journal.pone.0171748.t001
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Fig 7. In situ hybridization of CD24 expression in the adult human brain. (A) A schematic of the medulla oblongata at the level of the
pyramid (p), solitary nucleus (s), and the olivary nucleus (o). (B) CD24 transcripts in the dorsal motor nucleus of the vagal nerve. (C)
Neurons expressing CD24 in the nucleus ambiguus. (D) A schematic of the midbrain at the level of the red nucleus (r) and the neuromelanin
+ dopamine neurons (in grey). (E) An individual neuromelanin+ cell close to the midline weakly expressed CD24 (see inset for higher
magnitude). (F) Neuromelanin+ cells in the SNpc, however, are void of CD24 labelling. (G) The lining of the subventricular zone (svz) at the
level of the thalamus presented strong CD24 expression. (H) CD24 expression in the dentate gyrus (DG) and CA2 region of the
hippocampus. (I) Weakly labelled CD24+ cell bodies in the amygdala. The scale bar in panel I represents 150μm in panels B and C, 100μm
in panels E and F, and 250μm in panels G-I.
doi:10.1371/journal.pone.0171748.g007
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Our initial expression analysis confirmed and extended previous reports of Cd24 expression
in the rodent brain ([33]; Allen Institute for Brain Science. Allen Mouse Brain Atlas [Internet].
Available from: http://mouse.brain-map.org/experiment/show/79591541) and also provides
unique data on the expression of CD24 in the human CNS. Similarities in expression localisa-
tion across species were of interest, especially in evolutionarily older structures such as the
brainstem (e.g. the DmnV and the hypoglossal nucleus). The absence of CD24 expression in
the human SNpc, however, was particularly striking, although cross-species differences in
gene expression between mice and humans in midbrain DA neurons has been previously
reported. Orthodenticle Homeobox 2 (OTX2), for example, is a transcription factor that is
expressed by midbrain DA progenitors during development in both mice and humans, and
defines the VTA subpopulation in the mouse adult brain, but it is not expressed in any mid-
brain DA neurons in aged humans [47]. Of the 18 human midbrains analysed in the present
study, only one had any CD24 expression in neuromelanin+ cells, and those cells resided in
the more medially located VTA population. As indicated in the results section, that particular
case had other pathologies which complicates the interpretation of this finding. Despite this
absence of CD24 in the human adult midbrain DA neurons, we were still interested in assess-
ing possible functions of CD24 in the mouse SNpc DA neurons.
The absence of a phenotype in the midbrain DA system of the Cd24-/- mouse—out to 2
years of age—indicates that the gene is not required for the normal anatomical development
or maintenance of this population of neurons. While this lack of phenotype was useful for sub-
sequent disease modelling experiments, our analysis could not cover all aspects of DA neuro-
nal function (such as dopamine release, etc). It has been reported that Cd24 inhibits the
extension and collateral branching of neurites through its interactions with neural recognition
molecule L1 [48,49], thus in the absence of the gene it could be hypothesized that neurons
expressing Cd24 in the adult brain may exhibit more neurites. Given the density of normal
SNpc TH+ axonal arborisations, any increase in branching was difficult to analyse in the
Cd24-/- mouse and further microscopic analysis may reveal some subtle specific differences.
Cd24 also has a role in synaptic transmission [37]. In the absence of Cd24, neuromuscular
junctions exhibited synaptic depression, cyclical periods of complete transmission failure, and
a reduction in the pool of recycling vesicles in the terminals [37]. Thus, although it was not
investigated in the current study, looking at synaptic transmission in the SNpc DA neurons of
Cd24-/- mice would be of interest.
The modelling of PD (using striatally delivered 6-OHDA) in the Cd24-/- mouse showed
that the absence of the gene had no impact on the survival of the SNpc DA neurons. However,
while CD24 does not exhibit direct neuroprotection, it may be important in mediating the
neuroprotective effects of other agents such as GDNF. Thus, we sought to investigate this
using AAV-GDNF transfection and 6-OHDA lesions in Cd24-/- and wild-type mice and
found that there was a greater TH+ fibre density loss in the striatum of the AAV-GDNF/
6-OHDA Cd24-/- mice. Previously we have demonstrated that the fibre loss following striatal
delivery of 6-OHDA in the mouse is very rapid (>60% of eventual fibre loss occurring within
the first 24 hours), and that from 3 days post-lesion the extent of fibre loss remains constant
[23]. In the current study, while AAV-GDNF preserved the DA cell bodies in the SNpc of the
Cd24-/- mice, it was not able to rescue the density of striatal TH+ fibres at three weeks post-
lesion. The oxidation and washout of 6-OHDA in the brain within the first 24 hours would
render a delayed/slowed loss of TH+ fibres unlikely. One confounding aspect of this result,
however, is why the absence of CD24 does not result in a similar loss of TH+ fibres to that
observed in the 6-OHDA lesioned control mice. This suggests that additional GDNF-related
pathways may be involved, resulting in only a partial reduction in the neuroprotective effect of
GDNF at the neurite level. This effect, though, does raise the possibility that CD24 may be
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playing a role in normal DA neurite outgrowth–an area we are now investigating further in
vitro.
Many Tgf-β family members are known to up-regulate the expression of CD24. Lentiviral
delivery of GDNF into the striatum resulted in an increase in Cd24 expression in the rodent
SNpc [44], and increased Cd24 promoter activity and Cd24 mRNA results from forced expres-
sion of Artemin [50]. Recently, a reciprocal relationship between CD24 and TGF-β3 in bone
marrow-derived stromal cells has been reported [51]. Given the lack of CD24 expression in the
human DA neurons and the reduction in TH+ fibre density in the AAV-GDNF/6-OHDA in
the present study, it is tempting to speculate on the role of CD24 and the likely success of clini-
cal trials involving the delivery GDNF to the striatum in people with PD.
As to a specific role CD24 may be playing in PD, it is difficult to speculate. While CD24 has
not been associated with PD, polymorphisms in this gene does result in increased risk and pro-
gression of several autoimmune diseases, including multiple sclerosis [52,53], Crohn’s disease
[54], and rheumatoid arthritis [55]. This may be relevant to PD given the recent interest in the
possibility that PD may have a primary neuroinflammatory component. In addition while
there is a lack of CD24 expression in the DA neurons of the midbrain in humans, the selective
expression in other vulnerable regions of the PD brain (particularly in the lower brain stem)
suggests that this is a gene worthy of further investigation as it may have some indirect role in
the disease process.
In conclusion, we have shown that CD24 has some commonality of expression with the
widespread distribution of pathology seen in PD, although we have been unable to show any
causal links between this glycoprotein and the loss of dopamine cells in the mouse model of
PD. Nevertheless, we have shown some association between the effects of a known neuro-
trophic factor for dopaminergic nigral neurons, GDNF, and CD24 expression. This merits fur-
ther exploration not only as this agent is in clinical trials in patients with PD but also because
the benefits of GDNF have been shown to critically depend on other pathways within the stria-
tum [56].
Supporting information
S1 Fig. In situ hybridization of Cd24 transcript expression on coronal sections of brains
from 8-week old adult mice. (A) Cd24 transcript (red; with haematoxylin counterstain)
expression is present in the olfactory bulbs. (B) A high magnification image of the dashed
boxed region in panel A, providing Cd24 expression overlapped with TH immunofluorescent
staining in the olfactory bulb. (C) Robust Cd24 transcripts in the rostral migratory stream
(RMS) and ’salt and pepper’ distribution throughout the frontal cortex. (D) Strong expression
of Cd24 in the lining of the ventricular zone (VZ) across all levels of the striatum (Str). (E)
Cd24 expression at the level of the thalamus. (F) The dashed-boxed area of panel E, providing
a high magnification image of Cd24 expression in the suprachiasmatic nucleus (SCN). (G) An
image of the third ventricle (3V) at the level of the caudal hypothalamus; arrows indicating the
area of no Cd24 expression (a consistent feature across 3 brains analysed). (H) Cd24 expression
in the cortex, layers are indicated on the right-hand side. (I) Cd24 expression in the hippocam-
pus, especially within the dentate gyrus (DG) and CA1, but not CA3. (J) Immunofluorescent
staining of TH expression in the Striatum (Str) and the neighbouring globus pallidus (GP), in
combination with Cd24 expression in the Reticular nucleus of the thalamus (RT) and lining of
the VZ. (K) In the hindbrain, Cd24 is present in the parabigeminal nucleus (PBG), nucleus of
the trapezoid body (NTB), and weakly expressed in the dorsal raphe nuclei (RN) and Peduncu-
lopontine nuclei (PPN). (L) In the brainstem, Cd24 expression was observed in the cerebellar
nuclei (CBN), medial vestibular nucleus (MV), facial motor nucleus (VII), and ventral cochlear
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nucleus (VCO). The scale bar in panel L represents 5mm in panel E,1mm in panels A, C and
K, 800μm in panel L, 500μm in panels D, F, G, I and J, and 100μm in panels B and H.
(TIF)
S2 Fig. Immunohistochemistry of CD24 expression on an 8-week old adult mouse brain.
(A) Strong CD24 expression in the olfactory bulb (especially the glomerular layer and rostral
migratory stream). (B) In the entire lining of the ventricular zone at the level of the striatum,
CD24 is present. (C) CD24 protein is observed the Reticular nucleus of the thalamus (RT). (D)
At the level of the thalamus, strong CD24 expression is seen in the amygdala and the lateral
posterior thalamic nucleus (mediocaudal part; LPMC). (E) The LPMC expression is main-
tained into the midbrain, where there is also very strong staining in the zonal layer and weaker
expression in the ventral layers of the superior colliculus (SC). (F) The SC expression of CD24
is maintained throughout the midbrain. There is also CD24 staining surrounding the medial
geniculate nucleus (MG). (G) Robust expression in the red nucleus. (H) In the hindbrain,
there is strong expression in the nucleus of lateral lemniscus (NLL) and the superior olivary
complex (SOC). (I-L) CD24 expression on sections of brain from the Cd24-/- mouse, demon-
strating a lack of protein labelling at all levels of the CNS. Numbers on the periphery represent
the plane of the coronal section relative to bregma. Scale bar in panel D represents 3mm in
images A-D and I-L, and 1.5mm for images E-H.
(TIF)
S3 Fig. Immunohistochemistry of TH expression in the Cd24-/- mouse. The DA system of
the 2-year old Cd24-/- mouse (left column) differs little from that of the age-matched Cd24+/+
mouse (right) across all of the coronal planes examined. Numbers on the periphery represent
the plane of the coronal section relative to bregma. Scale bar represents 3mm.
(TIF)
S4 Fig. Immunohistochemistry demonstrating the lack of GDNF neuroprotection at the
level of the striatal neurites following 6-OHDA lesion. (A) GDNF expression in the striatum
of a Cd24-/- mouse one-month post-AAV-GDNF striatal delivery. (B) AAV-GDNF transfec-
tion of the striatum resulted in an increase in CD24 expression in the SNpc on the injected
side of the brain in Cd24+/+ mouse, but not Cd24-/- mice (B’). (C-F) Three weeks post-
6-OHDA delivery to the striatum, both groups of AAV-GDNF mice (both Cd24+/+ and
Cd24-/-) presented varying levels of TH+ fibre loss in the striatum. (C-C’’ and D-D’’ represent
the worst cases in the Cd24+/+ and Cd24-/- groups, respectively; while E-E’’ and F-F’’ represent
the best cases in the Cd24+/+ and Cd24-/- groups, respectively. Numbers on the periphery rep-
resent the plane of the coronal section relative to bregma. Scale bar in panel A represents 2mm
in panel A,500μm in panels B-B’, and 1mm in panels C-F’’.
(TIF)
S5 Fig. Fibre density analysis and stereological estimations at 21 days post 6-OHDA lesion
compared to 12 and 70 day timepoints. (A) TH+ fibre density analysis of the striatum at each
of the different time points used in this study, presented as percentage of the unlesioned intact
striatum. (B) A representative example of the lesioned striatum of a WT mice at 21 days post
6-OHDA lesion. (C) Stereological estimations of TH+ cells in the SN of WT mice at each of
the different time points used in this study, presented as percentage of the unlesioned intact
SN. (D) Representative sections of midbrain at the level of fasciculus retroflexus (FR) and the
medial lemniscus (ML) are presented. Numbers in the bottom right corner of panels B&D are
co-ordinates representing the planes of the coronal section relative to bregma. Scale bar in
panel D represents 2mm in panel B, and 500μm in panel D.
(TIF)
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